Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study

GENEVA (SEPT. 18, 2024) – Relief Therapeutics Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY), a biopharmaceutical company, announced the completion of dosing in its proof-of-concept clinical study of RLF-OD032 for phenylketonuria (PKU). PKU is a rare inherited disorder affecting phenylalanine metabolism.

The study's primary objectives include comparing RLF-OD032 to currently marketed sapropterin dihydrochloride, focusing on bioavailability under fed and fasting conditions. The Company expects topline results in October 2024, which will guide further development toward a pivotal trial and potential regulatory submission in the U.S.

RLF-OD032 is a highly concentrated liquid formulation of sapropterin dihydrochloride, designed to lower blood phenylalanine in PKU patients. This innovative formulation aims to improve compliance and is the first ready-to-use liquid form of sapropterin dihydrochloride.